KR100905747B1 - Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin - Google Patents

Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin Download PDF

Info

Publication number
KR100905747B1
KR100905747B1 KR1020070070841A KR20070070841A KR100905747B1 KR 100905747 B1 KR100905747 B1 KR 100905747B1 KR 1020070070841 A KR1020070070841 A KR 1020070070841A KR 20070070841 A KR20070070841 A KR 20070070841A KR 100905747 B1 KR100905747 B1 KR 100905747B1
Authority
KR
South Korea
Prior art keywords
anthocyanin
nsaids
gastric
black rice
gastritis
Prior art date
Application number
KR1020070070841A
Other languages
Korean (ko)
Other versions
KR20090007146A (en
Inventor
장효일
박영삼
Original Assignee
고려대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려대학교 산학협력단 filed Critical 고려대학교 산학협력단
Priority to KR1020070070841A priority Critical patent/KR100905747B1/en
Publication of KR20090007146A publication Critical patent/KR20090007146A/en
Application granted granted Critical
Publication of KR100905747B1 publication Critical patent/KR100905747B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/55Liquid-liquid separation; Phase separation

Abstract

본 발명은 안토시아닌을 함유하는 비스테로이드성 항염증제(NSAIDs)에 의해 유발된 위염, 위궤양 치료용 조성물에 관한 것으로, 더욱 구체적으로 흑미로부터 추출된 안토시아닌을 유효성분으로 함유하는 것을 특징으로 하는, 비스테로이드성 항염증제(NSAIDs)에 의해 유발된 위염, 위궤양 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for treating gastritis and gastric ulcer caused by nonsteroidal anti-inflammatory drugs (NSAIDs) containing anthocyanins, and more particularly, characterized in that it contains anthocyanins extracted from black rice as an active ingredient. It relates to a composition for preventing and treating gastritis, gastric ulcer caused by anti-inflammatory agents (NSAIDs).

본 발명에 따르면, 흑미로부터 추출된 안토시아닌이 NSAIDs에 의해 유발된 위염 및 위궤양에 효과가 있는 지를 지질과산화 억제, SOD 활성 증가, 카탈라아제 활성 증가, 글루타치온 페록시다아제 활성 증가를 통하여 확인하였다. 따라서 상기 흑미-유래 안토시아닌으로부터 비스테로이드성 항염증제에 의해 유발된 위염 및 위궤양에 대한 치료 효과를 기대할 수 있다.According to the present invention, whether anthocyanin extracted from black rice is effective in gastritis and gastric ulcer induced by NSAIDs was confirmed through inhibition of lipid peroxidation, increased SOD activity, increased catalase activity, and increased glutathione peroxidase activity. Therefore, the therapeutic effect on gastritis and gastric ulcer induced by nonsteroidal anti-inflammatory agent from the black rice-derived anthocyanin can be expected.

안토시아닌, 흑미, 위염, 위궤양, 나프록센 Anthocyanin, black rice, gastritis, gastric ulcer, naproxen

Description

안토시아닌을 함유하는 비스테로이드성 항염증제에 의해 유발된 위염 및 위궤양 치료용 조성물 {Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin}Composition for the treatment of gastritis and gastric ulcer induced by nonsteroidal anti-inflammatory agent containing anthocyanin {Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin}

본 발명은 안토시아닌을 함유하는 비스테로이드성 항염증제에 의해 유발된 위염, 위궤양 치료용 조성물에 관한 것으로, 더욱 구체적으로 흑미로부터 추출된 안토시아닌을 유효성분으로 함유하는 것을 특징으로 하는, 비스테로이드성 항염증제(NSAIDs)에 의해 유발된 위염, 위궤양 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for treating gastritis and gastric ulcer caused by a nonsteroidal anti-inflammatory agent containing anthocyanin, and more particularly, an anthocyanin extracted from black rice as an active ingredient, a nonsteroidal anti-inflammatory agent (NSAIDs) It relates to a composition for preventing and treating gastritis and gastric ulcer caused by a).

다수의 비스테로이드 항염증제(Nonsteroidal anti-inflammatory drugs, NSAIDs)는 임상적으로 소염, 진통제로서 널리 이용되어 왔으나, NSAIDs를 복용한 환자에게 가장 심각한 부작용으로 나타나는 것이 위장관계 질환이며, NSAIDs를 사람 및 동물에 투여 시 출혈(bleeding), 궤양(ulceration), 천공(perforation) 등을 포함한 심각한 위점막 손상을 유발하는 것으로 알려져 있다. 나프록센(Naproxen)은 NSAIDs에 속하는 비코르티코스테로이드계 약물 (noncorticosteroid drug)로서, 래 트(Rat)에 경구투여시 위의 강(antrum) 부위에 위염 및 위궤양(ulcerations)을 유발하는데, 나프록센에 의해 유발된 위궤양(gastric antral ulceration)의 발생에는 산소 자유라디칼(oxygen free radicals)의 생성과 지질 과산화(lipid peroxidation)가 결정적인 역할을 한다. 위장관계 궤양은 공격인자(위산, 펩신, 미주신경의 자극, 가스트린의 분비, 위벽세포의 증가 및 위점막의 손상 등)와 방어인자(중탄산 분비, 점액생산, 점막생성력, 국소점막 혈류 및 프로스타글란딘 등) 사이의 균형이 파괴될 때 발생하는데, 나프록센과 같은 NSAIDs로 인한 궤양은 프로스타글란딘의 합성이 저해되는 데서 기인한다. 이러한 궤양의 치료제로는 공격인자를 억제하는 제산제, 항-펩신제 등이 있고 방어인자를 강화하는 점막보호제, 점막혈류강화제 등이 있으며 위액분비를 억제하는 H2-수용체 길항제 등이 있다. 최근 헬리코박터 피롤리가 소화성 궤양의 중요한 원인균으로 인정됨에 따라 항균제도 위장관계 궤양 치료제로서 이용되고 있다.Although many nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely used clinically as anti-inflammatory and analgesics, the most serious side effects of patients taking NSAIDs are gastrointestinal disorders. Administration is known to cause severe gastric mucosal damage, including bleeding, ulceration, perforation, and the like. Naproxen is a noncorticosteroid drug belonging to NSAIDs that causes gastritis and gastric ulcerations in the antrum of the stomach when orally administered to rats, caused by naproxen The generation of gastric antral ulceration plays a crucial role in the generation of oxygen free radicals and lipid peroxidation. Gastrointestinal ulcers include attack factors (gastric acid, pepsin, vagus nerve stimulation, gastrin secretion, increased gastric wall cells and damage to gastric mucosa) and protective factors (bicarbonate secretion, mucus production, mucosal production, local mucosal blood flow and prostaglandins). Occurs when the balance between) is disrupted, as ulcers caused by NSAIDs such as naproxen are caused by the inhibition of prostaglandin synthesis. Treatment agents for such ulcers include antacids that inhibit attack factors, anti-pepsin agents, mucoprotective agents that enhance defense factors, mucosal blood flow enhancers, and the like, and H2-receptor antagonists that suppress gastric secretion. Recently, as Helicobacter pyrroli has been recognized as an important causative agent of peptic ulcer, antimicrobial agents have been used to treat gastrointestinal ulcers.

한편, 안토시아닌(anthocyanin)은 자연계에 널리분포하는 플라보노이드 계통의 색소로서, 강력한 항산화 활성(antioxidant activity)을 갖고 있는 것으로 알려져 있다. 안토시아닌은 활성산소 및 자유라디칼 제거능력이 존재한다. 이러한 능력은 활성산소종(ROS)의 공격으로부터 유발되는 많은 병들에 대한 방어 기작을 나타내는 것으로 여겨진다.On the other hand, anthocyanins are flavonoid pigments widely distributed in nature and are known to have strong antioxidant activity. Anthocyanins have the ability to remove free radicals and free radicals. This ability is believed to represent a defense mechanism against many diseases resulting from the attack of reactive oxygen species (ROS).

이에, 본 발명자들은 상기 종래기술들의 문제점들을 극복하기 위하여 예의 연구노력한 결과, 흑미로부터 추출된 안토시아닌이 지질과산화 억제, SOD 활성 증가, 카탈라아제 활성 증가, 글루타치온 페록시다아제 활성 증가에 효과가 있음을 확인함으로써, 비스테로이드성 항염증제에 의해 유발된 위염 및 위궤양 치료에 효과가 있음을 확인하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors have made intensive studies to overcome the problems of the prior art, and confirmed that anthocyanin extracted from black rice is effective in inhibiting lipid peroxidation, increasing SOD activity, increasing catalase activity, and increasing glutathione peroxidase activity. By doing so, it was confirmed that it is effective in the treatment of gastritis and gastric ulcer caused by nonsteroidal anti-inflammatory drugs, thereby completing the present invention.

따라서, 본 발명의 주된 목적은 비스테로이드성 항염증의 복용으로 유발된 위염 및 위궤양에 대한 안토시아닌의 치료적 적용 가능성을 확인하고, 그 신규한 용도를 제공하는 데 있다.Therefore, the main object of the present invention is to identify the therapeutic applicability of anthocyanin to gastritis and gastric ulcer caused by taking nonsteroidal anti-inflammatory and to provide its novel use.

본 발명의 한 양태에 따르면, 본 발명은 안토시아닌을 유효성분으로 함유하는 비스테로이드성 항염증제(NSAIDs)에 의해 유발된 위염, 위궤양 예방 및 치료용 조성물을 제공한다.According to one aspect of the invention, the present invention provides a composition for the prevention and treatment of gastritis, gastric ulcer caused by nonsteroidal anti-inflammatory agents (NSAIDs) containing anthocyanin as an active ingredient.

본 발명의 조성물에서, 상기 안토시아닌(anthocyanin)은 대개 천연색소로서 식물로부터 추출되어 사용되고 있으므로 자색고구마, 검정콩, 검정참깨, 복분자, 적포도, 블루베리, 오디 등으로부터 추출된 안토시아닌을 유효성분으로 함유될 수 있으나, 흑미로부터 추출된 안토시아닌을 유효성분으로 함유하는 것이 바람직하다. 본 발명의 실시예에서는 흑미 유래 안토시아닌을 추출하기 위하여 생리활성성분의 함유량이 특히 높은 부분인 흑미의 겨를 사용하였다.In the composition of the present invention, the anthocyanin (anthocyanin) is usually extracted from the plant as a natural pigment is used to contain anthocyanin extracted from purple sweet potato, black beans, black sesame, bokbunja, red grapes, blueberries, udi as an active ingredient However, it is preferable to contain anthocyanin extracted from black rice as an active ingredient. In the embodiment of the present invention, in order to extract the anthocyanin derived from black rice, the bran of black rice, which is a portion having a particularly high content of physiologically active ingredients, was used.

본 발명에 있어서, 상기 안토시아닌은 물, 알코올과 같은 친수성 유기용매 또는 이들의 혼합용매로도 추출하여 천연추출물의 여과 및 정제과정에 일반적으로 사용되는 여러 방법으로 제조될 수 있으나, 바람직하게는 흑미의 겨를 에탄올로 추출한 후 여과지로 여과하고, 이온교환수지가 충진된 컬럼을 사용하여 분리된 것을 특징으로 한다. 본 발명의 실시예에서는 상기 여과지로는 Whatman No.1 filter paper를 사용하였고, 이온교환수지로는 Amberlite XAD7 resin을 사용하였다.In the present invention, the anthocyanin may be prepared by various methods generally used for filtration and purification of natural extracts by extracting with a hydrophilic organic solvent such as water, alcohol, or a mixed solvent thereof, preferably black rice The bran was extracted with ethanol, filtered through a filter paper, and separated using a column filled with an ion exchange resin. In the embodiment of the present invention, Whatman No. 1 filter paper was used as the filter paper, and Amberlite XAD7 resin was used as the ion exchange resin.

본 발명의 조성물에서, 상기 비스테로이드성 항염증제는 나프록센(Naproxen)인 것을 특징으로 한다. 본 발명의 나프록센(Naproxen)은 NSAIDs에 속하는 비코르티코스테로이드계 약물 (noncorticosteroid drug)로서, 래트(Rat)에 경구투여시 위의 강(antrum) 부위에 위염 및 위궤양(ulcerations)을 유발하는데, 나프록센에 의해 유발된 위궤양(gastric antral ulceration)의 발생에는 산소 자유라디칼(oxygen free radicals)의 생성과 지질 과산화(lipid peroxidation)가 결정적인 역할을 한다. 따라서 본 발명의 조성물은 상기 산소 자유라디컬의 생성을 억제 및 지질 과산화 방지를 목적으로 항산화작용을 유도하기 위하여 흑미-유래 안토시아닌을 유효성분으로 함유하고 있다.In the composition of the present invention, the nonsteroidal anti-inflammatory agent is characterized in that naproxen (Naproxen). Naproxen of the present invention is a noncorticosteroid drug belonging to NSAIDs, which causes gastritis and gastric ulcerations in the antrum of the stomach when orally administered to rats. The generation of gastric antral ulceration caused by the production of oxygen free radicals (lipid peroxidation) plays a decisive role. Therefore, the composition of the present invention contains black rice-derived anthocyanin as an active ingredient in order to induce antioxidant activity for the purpose of inhibiting the production of oxygen free radicals and preventing lipid peroxidation.

본 발명의 조성물에서, 상기 조성물은 생체 내에서 지질과산화를 억제하고 항산화효소를 활성화시키는 것을 특징으로 한다. 본 발명의 NSAIDs에 의해 유발된 위염 및 위궤양은 상기 언급한 바와 같이, 생체 내에서 지질과산화를 억제하고 카탈라아제 및 글루타치온 페록시다아제와 같은 항산화작용을 유도하는 항산화 효소를 활성화함으로써 예방하거나 치료될 수 있다. 본 발명의 실시예에서는 흑미-유래 안토시아닌이 투여된 쥐에서 지질과산화 억제와 항산화 효소의 활성 효과가 현저하게 증가됨을 확인하였다.In the composition of the present invention, the composition is characterized by inhibiting lipid peroxidation and activating antioxidant enzymes in vivo. Gastritis and gastric ulcer caused by the NSAIDs of the present invention, as mentioned above, can be prevented or treated by activating antioxidant enzymes that inhibit lipid peroxidation in vivo and induce antioxidant activities such as catalase and glutathione peroxidase. have. In the embodiment of the present invention, it was confirmed that lipid peroxidation inhibitory activity and antioxidant enzyme activity were markedly increased in the rats administered with black rice-derived anthocyanin.

본 발명의 흑미-유래 안토시아닌이 상기와 같은 예방 및 치료용 조성물로 이용되기 위해서는 약제학적 분야에서 공지된 방법에 의해 제조될 수 있으며, 그 자 체 또는 약학적으로 허용되는 담체, 부형제, 희석제 등과 혼합하여 분말, 과립, 정제, 캡슐제 또는 주사제 등의 제형으로 제조되어 사용될 수 있다. 또한 이들은 경구 또는 비경구로 투여될 수 있다.The black rice-derived anthocyanin of the present invention may be prepared by a method known in the pharmaceutical art in order to be used as a composition for preventing and treating the above, and may be mixed with itself or a pharmaceutically acceptable carrier, excipient, diluent, and the like. It can be prepared and used in the form of powders, granules, tablets, capsules or injections. They can also be administered orally or parenterally.

본 발명에 따른 안토시아닌을 유효성분으로서 투여하는 투여량은 환자의 연령, 성별, 상태, 질병의 증상에 따라 적절히 선택될 수 있으며, 바람직하게는 1일 0.1 내지 100 mg/kg의 안토시아닌이 투여될 수 있다.The dosage for administering anthocyanin according to the present invention as an active ingredient may be appropriately selected according to the age, sex, condition, and symptoms of the disease of the patient, and preferably, 0.1 to 100 mg / kg of anthocyanin may be administered per day. have.

본 발명에서는 NSAIDs에 의해 유발되는 위궤양 실험쥐 모델을 이용하여 안토시아닌의 생체 내에서의 예방 및 치료효과를 확인함으로써, 안토시아닌을 유효성분으로 함유하는 NSAIDs에 의한 위염 및 위궤양 치료용 조성물을 제공하게 되었다. 특히, 나프록센은 관절염 환자 치료 등에 다른 NSAIDs보다 더욱 보편적으로 사용되고 있을 뿐만 아니라, 나프록센에 의한 위궤양은 주로 위의 앤트럼(gastric antrum)에서 유발되므로, 실제로 인간의 위궤양이 앤트럼 부위에 발생하는 점과 부합된다. 따라서 본 발명에서는 실험쥐에서 궤양(ulceration)을 유발하기 위한 NSAID로서 나프록센을 선택하였으며, 이러한 나프록센에 의해 유발된 위 앤트럴 궤양 모델(naproxen-induced gastric antral ulcer model)에서 안토시아닌의 우수한 항궤양 효과를 확인함으로써, 기존보다 개량된 위염 및 위궤양 치료 용도를 제공하게 되었다.In the present invention, by using the gastric ulcer mouse model induced by NSAIDs to confirm the prevention and treatment effect of anthocyanin in vivo, it was to provide a composition for treating gastritis and gastric ulcer by NSAIDs containing anthocyanin as an active ingredient. In particular, naproxen is more commonly used than other NSAIDs in the treatment of arthritis patients, and gastric ulcers caused by naproxen are mainly induced in the gastric antrum. Conforms. Therefore, in the present invention, naproxen was selected as an NSAID for inducing ulceration in rats, and an excellent anti-ulcer effect of anthocyanin in the naproxen-induced gastric antral ulcer model induced by such naproxen This has led to improved use of gastritis and gastric ulcer use.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail with reference to Examples. Since these examples are only for illustrating the present invention, the scope of the present invention is not to be construed as being limited by these examples.

이상 설명한 바와 같이, 본 발명에 따르면 흑미로부터 추출된 안토시아닌은 생체 내에서 지질과산화 억제와 함께 SOD, 카탈라아제, 및 글루타치온 페록시다아제와 같은 항산화효소의 활성을 증가시키기 때문에, NSAIDs에 의해 유발된 위염 및 위궤양에 대하여 뛰어난 치료효과를 나타내는 치료제 및 기능식품의 개발에 유용하게 사용될 수 있을 것으로 기대된다.As described above, according to the present invention, the anthocyanin extracted from black rice increases the activity of antioxidant enzymes such as SOD, catalase, and glutathione peroxidase in combination with lipid peroxidation in vivo, and therefore, gastritis induced by NSAIDs And it is expected to be useful in the development of therapeutics and nutraceuticals that exhibit excellent therapeutic effects against gastric ulcers.

실시예 1: 흑미로부터 안토시안닌의 추출 및 분석Example 1 Extraction and Analysis of Anthocyanins from Black Rice

안토시아닌 추출에 사용된 흑미(흑진주벼)는 농촌진흥청으로부터 얻었다. 상기 흑미로부터 안토시아닌을 추출하는 과정은 다음과 같다. 도정된 흑미의 겨 0.5g을 0.% TFA(Trifluoroacetic acid)를 포함하는 에탄올에 침전시켜 24시간 둔다. 그런 다음 상기 에탄올 추출물을 Whatman NO.1 filter paper를 사용하여 필터링 시킨 후 회전증발(rotary evaporator)을 이용하여 완전히 건조시킨다. 상기 얻은 건조물을 100ml의 증류수에 녹인 후 Amberlite XAD7 레진을 사용하는 컬럼 크로마토그래피(column chromatograpy)에 충전시킨다. 상기 같이 이온교환 크로마토그래피를 수행하여 얻은 안토시아닌은 HPLC에 의해 분석되었다 (도 1).Black rice (black jinju rice) used for anthocyanin extraction was obtained from RDA. The process of extracting anthocyanin from the black rice is as follows. 0.5 g of bran of black rice is precipitated in ethanol containing 0.% TFA (Trifluoroacetic acid) and left for 24 hours. The ethanol extract is then filtered using Whatman NO.1 filter paper and then completely dried using a rotary evaporator. The obtained dried material was dissolved in 100 ml of distilled water and then packed into column chromatography using Amberlite XAD7 resin. Anthocyanins obtained by performing ion exchange chromatography as described above were analyzed by HPLC (FIG. 1).

도 1에서와 같이, 상기 흑미로부터 추출된 추출물이 단일 성분으로 이루어져 있으며 (도 1의 A), 상기 단일 성분은 안토시아닌임을 확인하였다 (도 1의 B).As shown in Figure 1, the extract extracted from the black rice consists of a single component (A of Figure 1), it was confirmed that the single component is anthocyanin (B of Figure 1).

실시예 2: 실험 동물군의 처리 및 나프록센으로 유도된 위궤양 모델 제조방법Example 2 Treatment of Experimental Animal Group and Method of Making Naproxen-Induced Gastric Ulcer Model

230~250 g의 7주령 수컷 흰쥐(Sprage-Dawley rats)를 대한 바이오링크에서 구입하였다. 실험용 쥐(rat)는 우리에 넣고 온도 22~24℃, 습도 70~75%, 12시간 light 및 12시간 dark로 조절된 방에서 사육하였으며 일반적인 사료(normal laboratory diet)를 먹였다. 실험용 쥐들은 실험 전 18시간 동안 금식 시켰으며, 첫번째 나프록센 투여 이후에는 실험 기간동안 사료와 수돗물을 제공하였다.230-250 g of 7-week old male rats (Sprage-Dawley rats) were purchased from Biolink. Rats were housed in cages and kept in a room controlled at a temperature of 22-24 ° C, a humidity of 70-75%, 12 hours light and 12 hours dark and fed a normal laboratory diet. The rats were fasted for 18 hours prior to the experiment. After the first naproxen dose, the rats were fed feed and tap water for the duration of the experiment.

나프록센(sodium salt)은 Sigma Chemical Co. (St Louis, MO)에서 구입하여 증류수에 녹여서 사용하였고 주사기(feeding needle)를 사용하여 연속적으로 경구투여 하였다. 안토시아닌은 사용하기 직전 증류수에 즉시 녹여 각각 5, 25, 50 ml/kg의 복용량으로 실험쥐에 경구 투여하였다. 나프록센(120 mg/kg dose range)은 하루에 두 번씩(09시, 21시) orogastric gavage에 의해 실험쥐에 투여되었다. 실험쥐는 나프록센을 투여하고 1-5일 후에 에테르 마취를 통해 죽였다. 실험쥐의 위(Stomach)는 greater curvature를 따라 절개하였으며 0.9% 식염수로 세척하였다.Naproxen (sodium salt) is Sigma Chemical Co. It was purchased from (St Louis, MO) and used in dissolved distilled water and continuously orally administered using a feeding needle. Anthocyanins were immediately dissolved in distilled water immediately before use and orally administered to mice at doses of 5, 25 and 50 ml / kg, respectively. Naproxen (120 mg / kg dose range) was administered to rats by orogastric gavage twice a day (09 and 21 o'clock). Mice were killed via ether anesthesia 1-5 days after naproxen. Stomach of rats was cut according to greater curvature and washed with 0.9% saline.

실험쥐들은 구체적으로 총 3그룹으로 나누었으며(그룹 당 8마리) 각 실험군은 다음과 같다. 정상군(Noral group)은 하루에 두 번 9시와 21시에 증류수(distilled water)를 다른 그룹과 동일한 용량으로 경구투여 하였다. 대조군(Control)은 나프록센(120 mg/kg)만을 하루 두 번 9시와 21시에 경구투여 하였다. 실험군(안토시아닌 투여군)은 나프록센(120 mg/kg)을 하루 두 번 9시와 21시에 경구투여한 후 안토시아닌을 각각 5, 25, 50 mg/kg 투여량으로 하루 두 번 9시와 21시에 orogastric gavage를 통해 투여하였다.The mice were specifically divided into 3 groups (8 animals per group). The normal group orally administered distilled water twice a day at 9 and 21 o'clock in the same dose as the other groups. Control group was orally administered naproxen (120 mg / kg) twice a day at 9 and 21 o'clock. The experimental group (Anthocyanin-administered group) was orally administered naproxen (120 mg / kg) twice a day at 9 and 21 o'clock, and then anthocyanin at 9, 9 and 21 hours twice a day at 5, 25 and 50 mg / kg doses, respectively. Administration via orogastric gavage.

또한, 여러 실험쥐의 위에서 통상적인 조직학적 평가(routine histological evaluation)방법에 의해 위궤양을 확인하였는데, 나프록센에 의한 위 손상(Gastric damage)은 궤양(ulcers)의 형태로 주로 확인되었다. 궤양은 위 점막 표면(gastric mucosal surface)을 관통(penetration)하는 깊이에 의해 육안으로 판단하였는데, 위 궤양은 주로 gastric antrum에서 확인되었고, gastric corpus에서는 발견되지 않았다.In addition, gastric ulcers were identified by routine histological evaluation of the stomach of several mice. Gastric damage by naproxen was mainly confirmed in the form of ulcers. Ulcers were visually judged by the depth penetrating the gastric mucosal surface. Gastric ulcers were identified mainly in the gastric antrum and not in gastric corpus.

실시예 3: 안토시아닌 투여에 의한 지질과산화의 변화 측정Example 3 Measurement of Changes in Lipid Peroxidation by Anthocyanin Administration

지질과산화(lipid peroxidation) 정도를 알아보기 위해 실험쥐(Rats)의 위 점막(gastric mucosa)에서 TBA(thiobarbituric acid) 반응체(reactants)의 레벨(level)을 측정하였다. 위점막을 균질화시킨 것(stomach homogenate)에 8.1% 소듐 도데실 설페이트(sodium dodecyl sulfate), 20% 아세트산(pH 3.5), 0.8% TBA를 넣고 1시간 동안 95℃에서 반응시켰다. 그런 다음 수돗물로 냉각하고 반응체(reactants)에 15:1 비율로 혼합한 n-부탄올 과 피리딘(15:1 v/v)을 넣고 1분 동안 강하게 흔들어주었다. 그리고 4000rpm에서 10분간 원심분리 하였다. 흡광도 (Absorbance)는 532 nm에서 측정하였으며 결과는 조직 중량(g) 당 MDA(nmole)로 표현하였다. 지질과산화 정도는 말론디알데하이드 테트라부틸암모늄염(malondialdehyde tetrabutylammonium salt)을 사용한 표준커브(standard curve)로부터 계산되었다.To determine the degree of lipid peroxidation, the level of TBA (thiobarbituric acid) reactants in the gastric mucosa of rats was measured. To homogenate the gastric mucosa (stomach homogenate) was added 8.1% sodium dodecyl sulfate, 20% acetic acid (pH 3.5), 0.8% TBA and reacted at 95 ℃ for 1 hour. Then, the mixture was cooled with tap water and n-butanol and pyridine (15: 1 v / v) mixed at a ratio of 15: 1 was added to the reactants, followed by strong shaking for 1 minute. And centrifuged for 10 minutes at 4000rpm. Absorbance was measured at 532 nm and the results were expressed in MDA (nmole) per g of tissue weight. The degree of lipid peroxidation was calculated from a standard curve using malondialdehyde tetrabutylammonium salt.

측정 결과, 도 2에서와 같이 지질과산화의 지표인 위 점막에서의 MDA(Malondialdehyde)의 농도는 정상군에서 156.92± 6.03 nmol/g of tissue였다. 대조군에서는 266.94± 8.0 nmol/g of tissue로 정상군에 비해 2배 가까이 높게 나타났다. 반면 안토시아닌을 5, 25, 50 mg/kg 투여한 군에서는 각각 232.43± 6.78, 185.59± 5.28 및 167.08± 9.91 nmol/g of tissue로 용량 의존적으로 지질과산화를 유의성 있게 감소시키는 것을 확인할 수 있었다. 모든 결과치는 평균± 표준편차로 표현되었고, 대조군과 정상군, 실험군 간의 유의성(P<0.05)을 비교할 때는 Tukey's studentized range test를 사용하여 유의성을 검사하였다.As a result, as shown in Figure 2, the concentration of MDA (Malondialdehyde) in the gastric mucosa, which is an indicator of lipid peroxidation, was 156.92 ± 6.03 nmol / g of tissue in the normal group. In the control group, 266.94 ± 8.0 nmol / g of tissue was nearly twice as high as the normal group. On the other hand, 5, 25, and 50 mg / kg of anthocyanin showed a significant dose-dependent decrease in lipid peroxidation with 232.43 ± 6.78, 185.59 ± 5.28 and 167.08 ± 9.91 nmol / g of tissue, respectively. All results were expressed as mean ± standard deviation, and when comparing the significance (P <0.05) between the control group, normal group and experimental group, Tukey's studentized range test was used.

실시예 4 : 안토시아닌 투여에 의한 SOD 활성 변화 측정Example 4 Measurement of Changes in SOD Activity by Administration of Anthocyanin

안토시아닌의 경구투여 후 실험쥐의 위점막에서의 SOD 활성을 측정하였다 실험은 25℃ 큐벳(cuvette)에서 3 mL의 0.1mM EDTA를 포함한 50 mM 인산칼륨 버퍼(pH 7.8)에서 수행하였다. 반응혼합물(reaction mixture)은 0.1 mM 페리사이토크롬 C(ferricytochrome c), 0.1 mM 잔틴(xanthine), 550 nm에서 분당 0.025 흡광도 단위(absorbance unit)의 페리사이토크롬 C(ferricytochrome C)의 환원율을 생산하기 위한 충분한 잔틴 옥시다아제(xanthine oxidase)를 포함시켰다. 균질화된 조직(Tissue homogenate)은 반응혼합물(0.1 mM EDTA를 포함한 50 mM 인산칼륨 버퍼(pH 7.8), 0.1 mM 페리사이토크롬 C, 0.1 mM 잔틴)과 혼합시켰다. Kinetic spectrophotometric 분석은 잔틴 옥시다아제(xanthine oxidase)를 첨가 하자마자 550 nm에서 시작하였다. 규정된 조건하에서, 사이토크롬 C의 환원을 50% 억제하는 데 요구되어지는 SOD의 양을 1 유닛(unit)으로 정의한다. 흡광도(Absorbance)는 550 nm에서 측정하였고 그 결과는 단백질 mg 당 units으로 표현하였다.SOD activity in gastric mucosa of mice after oral administration of anthocyanin was measured. Experiments were performed in 50 mM potassium phosphate buffer (pH 7.8) containing 3 mL of 0.1 mM EDTA in a 25 ° C. cuvette. The reaction mixture produces a reduction rate of 0.1 mM ferricytochrome C, 0.1 mM xanthine, and ferricytochrome C of 0.025 absorbance units per minute at 550 nm. Sufficient xanthine oxidase was included. Tissue homogenate was mixed with the reaction mixture (50 mM potassium phosphate buffer (pH 7.8) with 0.1 mM EDTA, 0.1 mM pericytochrome C, 0.1 mM xanthine). Kinetic spectrophotometric analysis started at 550 nm as soon as xanthine oxidase was added. Under defined conditions, the amount of SOD required to inhibit the reduction of cytochrome C by 50% is defined as 1 unit. Absorbance was measured at 550 nm and the results expressed in units per mg of protein.

측정 결과, 도 3에서와 같이 대조군의 SOD 활성은 4.30± 1.43 units/mg of protein으로 정상군(10.03± 1.43 units/mg of protein)과 비교할 때 유의성 있게 감소하였다. 그러나 안토시아닌 5, 25, 50 mg/kg 투여군은 각각 5.77± 0.75, 8.75± 1.38 및 9.73± 1.60 units/mg of protein으로 대조군과 비교할 때 각각 SOD 활성이 유의성 있게 증가하였다. 특히, 안토시아닌 투여량 25 mg/kg과 50 mg/kg에서의 SOD 활성은 대조군과 비교할 때 훨씬 높은 증가를 보였다.As a result, as shown in Figure 3, the SOD activity of the control group was 4.30 ± 1.43 units / mg of protein significantly decreased compared to the normal group (10.03 ± 1.43 units / mg of protein). However, anthocyanin 5, 25, 50 mg / kg group showed 5.77 ± 0.75, 8.75 ± 1.38 and 9.73 ± 1.60 units / mg of protein, respectively, and significantly increased SOD activity. In particular, SOD activity at anthocyanin doses of 25 mg / kg and 50 mg / kg showed a much higher increase compared to the control.

실시예 5 : 안토시아닌 투여에 의한 카탈라아제 활성 변화 측정Example 5 Measurement of Catalase Activity Change by Anthocyanin Administration

안토시아닌의 경구투여 후 실험쥐의 위점막에서 카탈라아제 활성(Catalase activity)은 Aebi(1974)의 방법에 따라 결정되었다. 반응혼합물(reaction mixture)은 pH 7.0인 50 mM 인산칼륨 버퍼와 10 mM H2O2로 구성되었다. 실험은 pH 7.0인 50 mM 인산칼륨 버퍼 1.9 mL, 10 mM H2O2 1 mL 및 균질화된 조직(tissue homogenate) 100 ㎕를 합하여 3mL에서 수행되었다. 규정된 조건 하에, 25℃, pH 7.0에서 분 당 1.0 μmole H2O2를 분해시키는데 요구되는 카탈라아제의 양을 1 유닛(unit)으로 정의하였다. 흡광도(Absorbance)는 240 nm에서 2분 동안 측정하였고 그 결과는 단백질 mg 당 units로 표현하였다.Catalase activity in the gastric mucosa of rats after oral administration of anthocyanin was determined according to the method of Aebi (1974). The reaction mixture consisted of 50 mM potassium phosphate buffer at pH 7.0 and 10 mM H 2 O 2 . The experiment was performed at 3 mL by combining 1.9 mL of 50 mM potassium phosphate buffer at pH 7.0, 1 mL of 10 mM H 2 O 2, and 100 μl of tissue homogenate. Under defined conditions, the amount of catalase required to degrade 1.0 μmole H 2 O 2 per minute at 25 ° C., pH 7.0 was defined as 1 unit. Absorbance was measured for 2 minutes at 240 nm and the results are expressed in units per mg of protein.

측정 결과, 도 4에서와 같이 나프록센을 투여한 대조군에서 카탈라아제 활성 은 5.2867± 1.6702 units/mg of protein으로 정상군(36.0850± 2.7979 units/mg of protein)과 비교할 때 유의성 있게 감소하였다. 반면 안토시아닌을 5, 25, 50 mg/kg 투여한 실험군에서는 각각 6.6600± 1.7739, 14.7325± 2.3110 및 34.6300± 2.4914 units/mg of protein으로 대조군과 비교할 때 유의성 있게 증가하였다. 특히, 특히, 안토시아닌 투여량 25 mg/kg과 50 mg/kg에서의 카탈라아제 활성은 대조군과 비교할 때 훨씬 높은 증가를 보였다.As a result, the catalase activity was 5.2867 ± 1.6702 units / mg of protein in the control group administered naproxen, as shown in Figure 4 significantly compared to the normal group (36.0850 ± 2.7979 units / mg of protein). On the other hand, in the experimental group administered anthocyanin 5, 25, 50 mg / kg 6.6600 ± 1.7739, 14.7325 ± 2.3110 and 34.6300 ± 2.4914 units / mg of protein, respectively, significantly increased compared to the control group. In particular, catalase activity at anthocyanin doses of 25 mg / kg and 50 mg / kg showed a much higher increase compared to the control.

실시예 6 : 안토시아닌 투여에 의한 글루타치온 페록시다아제 활성 변화 측정Example 6 Measurement of Changes in Glutathione Peroxidase Activity by Anthocyanin Administration

안토시아닌 경구투여 후 실험쥐의 위점막에서 글루타치온 페록시다아제(GSH-px) 활성은 Lawrence and Burk [1976] 방법의 변형된 방법에 따라 결정되었다. 반응혼합물(reaction mixture)은 glutathione peroxidase assay buffer(50 mM인산칼륨 버퍼 pH 8.0, 0.5 mM EDTA)와 NADPH assay reagent (5 mM NADPH, 42 mM GSH, 10 unit/mL glutathione reductase)로 구성되었다. 균질화된 용액(homogenate solution)와 50 mM 인산칼륨 버퍼를 가진 상청액 (supernatant fluid)의 샘플은 4℃, 1,000 g에서 10분 동안 원심분리 하여 준비하였다. 큐벳(Cuvette)에 glutathioneperoxidase assay buffer 900 ㎕, NADPH assay reagent 50 ㎕, 샘플 50 ㎕을 연속적으로 첨가하고 잘 혼합하였다(큐벳의 총 량은 1.00 mL). 반응은 30 mM tert-butyl hydroperoxide 또는 Cumene hydroperoxide (80%) 10 ㎕ 첨가에 의해 시작되었다. 흡광도(Absorbance)는 Wavelength: 340 nm/ Initial delay: 15 seconds/ Interval: 10 seconds/ Number of readings: 6에 의해 기록되고 측정되었다. 효 소(glutathione peroxidase)의 총량은 30 mM tert-butyl hydroperoxide와 Cumene hydroperoxide (80%)를 이용한 각각의 실험 결과 값의 합으로 결정하였다. GSH의 레벨(level)은 μmole/min/mg of protein의 용어로 표현하였다.Glutathione peroxidase (GSH-px) activity in the gastric mucosa of rats after oral administration of anthocyanin was determined according to a modified method of Lawrence and Burk [1976]. The reaction mixture consisted of glutathione peroxidase assay buffer (50 mM potassium phosphate buffer pH 8.0, 0.5 mM EDTA) and NADPH assay reagent (5 mM NADPH, 42 mM GSH, 10 unit / mL glutathione reductase). Samples of homonatate solution and supernatant fluid with 50 mM potassium phosphate buffer were prepared by centrifugation at 1,000 g for 10 minutes at 4 ° C. 900 μl of glutathioneperoxidase assay buffer, 50 μl of NADPH assay reagent and 50 μl of sample were continuously added to the cuvette and mixed well (the total amount of cuvette was 1.00 mL). The reaction was initiated by the addition of 10 [mu] l of 30 mM tert-butyl hydroperoxide or Cumene hydroperoxide (80%). Absorbance was recorded and measured by Wavelength: 340 nm / Initial delay: 15 seconds / Interval: 10 seconds / Number of readings: 6. The total amount of enzyme (glutathione peroxidase) was determined by the sum of the results of each experiment using 30 mM tert-butyl hydroperoxide and Cumene hydroperoxide (80%). The level of GSH is expressed in terms of μmole / min / mg of protein.

측정 결과, 도 5에서와 같이 나프록센을 투여한 대조군에서 GSH-px 활성은 5.62± 0.91 μmole/min/mg of protein으로 정상군(9.94± 0.24 μmole/min/mg of protein)과 비교할 때 유의성 있게 감소하였다. 반면 안토시아닌을 5, 25, 50 mg/kg 투여한 실험군에서는 각각 6.15± 0.62, 7.99± 0.72 및 9.34± 0.38 μmole/min/mg of protein으로 대조군과 비교할 때 유의성 있게 증가하였다.As a result, the GSH-px activity in the control group administered naproxen as shown in Figure 5 significantly reduced 5.62 ± 0.91 μmole / min / mg of protein compared to the normal group (9.94 ± 0.24 μmole / min / mg of protein) It was. On the other hand, in the experimental group administered anthocyanin 5, 25 and 50 mg / kg, it was significantly increased compared with the control group with 6.15 ± 0.62, 7.99 ± 0.72 and 9.34 ± 0.38 μmole / min / mg of protein, respectively.

실시예 7. 안토시아닌 투여에 의한 위 조직의 변화 관찰Example 7 Observation of Changes in Gastric Tissue by Anthocyanin Administration

쥐의 위 조직(Murine stomach tissues)은 10% 중성 포르말린(buffered formalin)으로 고정시키고 파라핀(paraffin)으로 포메한 다음, 4-μcm 두께로 절단하였다. 그런 다음 일반적 절차에 따라 헤마톡실린(hematoxylin)과 에오신(eosin)으로 염색하여 관찰하였다.Murine stomach tissues were fixed with 10% neutral formalin, foamed with paraffin, and cut into 4-μcm thick. Then, it was observed by staining with hematoxylin and eosin according to the general procedure.

결과를 도 6을 참조하여 살펴보면, 비-처리 쥐(Untreated rat) 즉, 아무것도 처리하지 않은 정상 쥐의 위점막(gastric mucosal) 사진을 나타내었고, 이와 비교하여 나프록센-처리 쥐(Naproxen-treated rat: NSAIDs 계열의 나프록센을 경구투여 하여 위궤양 유발 모델)에서는 gastric mucosal 부분이 떨어져 나간 것처럼 손상(damage) 받은 것이 관찰되었다. 그리고 안토시아닌 처리 쥐(Anthocyanin-pretreated rat: 항위궤양 물질인 흑미 유래 anthocyanin을 투여 후 나프록센을 경구투여)에서는 항위궤양 물질인 anthocyanin에 의해 gastric mucosal 부분이 나프록센만 처리한 실험군과 비교하여 손상을 적게 입은 것이 관찰되었다.Referring to FIG. 6, the gastric mucosal images of the untreated rats, that is, the normal rats treated with nothing were shown. In comparison, the Naproxen-treated rats: In gastric ulcer-induced model (NSAIDs), oral administration of naproxen, the gastric mucosal part was observed to be damaged. In the case of anthocyanin-pretreated rats (oral administration of naproxen after administration of anti-ulcer substance anthocyanin from black rice), the gastric mucosal portion of the gastric mucosal area was less damaged by the anti-ulcer substance anthocyanin than the experimental group treated with naproxen only. Was observed.

도 1은 흑미로부터 추출된 안토시아닌의 HPLC 분석 자료를 나타낸 것이다.Figure 1 shows the HPLC analysis data of the anthocyanin extracted from black rice.

도 2는 안토시아닌의 투여농도에 따른 지질과산화 정도를 측정한 것이다.2 is a measure of the degree of lipid peroxidation according to the concentration of anthocyanin.

도 3은 안토시아닌의 투여농도에 따른 SOD 활성을 측정한 것이다.Figure 3 measures the SOD activity according to the concentration of anthocyanin administration.

도 4는 안토시아닌의 투여농도에 따른 카탈라아제 활성을 측정한 것이다.Figure 4 measures the catalase activity according to the concentration of anthocyanin administration.

도 5는 안토시아닌의 투여농도에 따른 글루타치온 페록시다아제 활성을 측정한 것이다.5 is a measure of glutathione peroxidase activity according to the concentration of anthocyanin.

Claims (5)

삭제delete 삭제delete 흑미의 겨를 에탄올로 추출한 후 여과지로 여과하고 이온교환수지가 충진된 컬럼을 사용하여 분리된, 시아니딘 3-0-글루코사이드(Cyanidin 3-O-glucoside)와 페오니딘 3-0-글루코사이드(Peonidin 3-O-glucoside)로 구성된 안토시아닌을 유효성분으로 함유하는 비스테로이드성 항염증제(NSAIDs)에 의해 유발된 위염, 위궤양 예방 및 치료용 조성물. Cyanidin 3-O-glucoside and peonidine 3-0-glucoside (Cheondin 3-O-glucoside) isolated from a black rice bran extracted with ethanol, filtered through a filter paper and packed with an ion exchange resin. Gastric inflammation, gastric ulcer prevention and treatment composition caused by nonsteroidal anti-inflammatory drugs (NSAIDs) containing anthocyanin consisting of 3-O-glucoside) as an active ingredient. 제 3항에 있어서, 상기 비스테로이드성 항염증제는 나프록센(Naproxen)인 것을 특징으로 하는 조성물.4. The composition of claim 3, wherein the nonsteroidal anti-inflammatory agent is naproxen. 제 3항에 있어서, 상기 조성물은 생체내에서 지질과산화를 억제하고 항산화효소를 활성화시키는 것을 특징으로 하는 조성물.4. The composition of claim 3, wherein the composition inhibits lipid peroxidation and activates antioxidant enzymes in vivo.
KR1020070070841A 2007-07-13 2007-07-13 Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin KR100905747B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020070070841A KR100905747B1 (en) 2007-07-13 2007-07-13 Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070070841A KR100905747B1 (en) 2007-07-13 2007-07-13 Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin

Publications (2)

Publication Number Publication Date
KR20090007146A KR20090007146A (en) 2009-01-16
KR100905747B1 true KR100905747B1 (en) 2009-07-01

Family

ID=40488120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070070841A KR100905747B1 (en) 2007-07-13 2007-07-13 Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin

Country Status (1)

Country Link
KR (1) KR100905747B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022539710A (en) * 2019-06-27 2022-09-13 ジェービーケーラボ カンパニー リミテッド A composition for preventing, improving or treating gastritis or peptic ulcer comprising an anthocyanin-negatively charged polysaccharide complex as an active ingredient

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101336411B1 (en) * 2011-05-27 2013-12-04 한국식품연구원 Novel use of rice extract for improving, preventing or treating sleep disorders, anxiety, or depression
KR101644607B1 (en) * 2014-08-21 2016-08-03 대한민국(농촌진흥청장) Compositions for Preventing or Treating for Diseases Derived from Helicobacter pylori comprising Extract of Black Rice and Health Food thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040057234A (en) * 2002-12-26 2004-07-02 장유숙 Rice cake with mixed grain and Manufacturing method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040057234A (en) * 2002-12-26 2004-07-02 장유숙 Rice cake with mixed grain and Manufacturing method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Plant Foods for Human Nutrition 62(1), pp.1-6(2007.03.)*
논문4:Plant Foods Hum Nutr*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022539710A (en) * 2019-06-27 2022-09-13 ジェービーケーラボ カンパニー リミテッド A composition for preventing, improving or treating gastritis or peptic ulcer comprising an anthocyanin-negatively charged polysaccharide complex as an active ingredient

Also Published As

Publication number Publication date
KR20090007146A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
Stanely Mainzen Prince et al. Antioxidant action of Tinospora cordifolia root extract in alloxan diabetic rats
Belagihally et al. Gastroprotective properties of karanjin from Karanja (Pongamia pinnata) seeds; Role as antioxidant and H+, K+-ATPase inhibitor
Prakash et al. Anti-ulceral and anti-oxidative properties of" earthworm paste" of Lampito mauritii (Kinberg) on Rattus Norvegicus.
Sharma et al. Ulcer healing potential of Aegle marmelos fruit seed
Liu et al. Cytoprotection by propolis ethanol extract of acute absolute ethanol-induced gastric mucosal lesions
Sebai et al. Modulating and opposite actions of two aqueous extracts prepared from Cinnamomum cassia L. bark and Quercus ilex L. on the gastrointestinal tract in rats
KR100905747B1 (en) Compositions for curing NSAIDs-induced gastric antral ulceration comprising anthocyanin
KR101091025B1 (en) Composition for curing NSAIDs-induced gastric antral ulceration comprising the extract of Rubus coreanus
Christian et al. Antidiabetic property and antioxidant potentials of aqueous extract of Azadirachta indica leaves in streptozotocininduced diabetic rats
Maidadi et al. Efficacy of Rytigynia senegalensis Blume on free radical scavenging, inhibition of α-amylase and α-glucosidase activity, and blood glucose level
Vandi et al. Antihistaminergic and Anticholinergic Properties of the Root Bark Aqueous Extract of Diospyros mespiliformis (Ebenaceae) on Hypersecretion of Gastric Acid Induced in Wistar Rats
RU2429000C2 (en) Anti-gastritis and anti-ulcer substance contained in momordicae semen and separated from it momordica saponin
KR101231164B1 (en) A composition for inhibiting gastric damages induced by ethanol containing polysaccharides from Hizikia fusiformis
KR100759468B1 (en) Composition for prevention and treatment of anti-gout comprising purple pigments isolated from purple sweet-potato
Silawat et al. The mechanism of hypoglycemic and antidiabetic action of hydroalcholic extract of Cassia fistula Linn. in rats
Sharma et al. Cytoprotection mediated antiulcer effect of aqueous fruit pulp extract of Cucumis sativus
Maidadi et al. Research Article Efficacy of Rytigynia senegalensis Blume on Free Radical Scavenging, Inhibition of α-Amylase and α-Glucosidase Activity, and Blood Glucose Level
KR100759467B1 (en) Composition for prevention and treatment of anti-gout containing a compound isolated from inonotus obliquus or phellinus baumi
Patil Anti-Ulcer And Anti-Secretory Properties Of The Butea Monosperma (Lam) Bark Extracts With Relation To Anti-Oxidant Studies
US20110201568A1 (en) Phyotochemical composition and a process thereof
KR100552396B1 (en) Astaxanthin for curing NSAID-induced gastric damage
Hazarika et al. Anti-ulcer activity of ethanolic extract of Sesamum indicum seed on indomethacin-induced ulcer model and its antioxidant property in gastro-protection
KR102326592B1 (en) Method to extract natural product using dry ice and composition containing extract obtained therefrom
EP2052728B1 (en) Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia
KR20120113186A (en) Composition comprising oriental herbal extract for preventing or treating gastrointestinal disorder

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130405

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20140318

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee